Compare iShares MSCI Japan ETF (EWJ) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Japan ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? iShares MSCI Japan ETF trades at $94.5 (market cap $23.22B), while Spyre Therapeutics Inc. Common Stock trades at $78.4 (market cap $7.35B). The key difference: iShares MSCI Japan ETF is far larger — about 3.2× Spyre Therapeutics Inc. Common Stock's market cap, and iShares MSCI Japan ETF is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Japan ETF for 57 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| EWJ | SYRE | |
|---|---|---|
Market Cap | $23.22B | $7.35B |
Volume | 5,587,717 | 1,624,631 |
Sector | Broad Market / Factor | Health |
52-Week High | $99.32 | $108.92 |
52-Week Low | $79.49 | $22.18 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWJ, a US-listed ETF tracking Japanese equities, trades at $97.32 with no change on the day. Technical indicators show a bullish overall signal, with moving averages supporting an uptrend while oscillators remain neutral. Recent news highlights Japan's monetary policy shifts and international ETF outperformance, with the Nikkei 225 experiencing volatility amid rising bond yields and fiscal stimulus debates.
The outlook for EWJ is cautiously optimistic, driven by Japan's economic stimulus and potential yen strength, but risks include BOJ policy uncertainty and global yield pressures. Investors may find opportunity in Japan's AI and semiconductor exposure, though currency fluctuations and fiscal challenges pose headwinds for sustained gains.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
